These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8048270)

  • 1. Effect of lipids on glomerular injury and progression of renal disease.
    Keane WF
    Verh K Acad Geneeskd Belg; 1994; 56(2):91-104. PubMed ID: 8048270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipids and the progression of renal disease.
    Keane WF; O'Donnell MP; Kasiske BL; Schmitz PG
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S69-74. PubMed ID: 16989069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids and progressive renal failure.
    Keane WF
    Wien Klin Wochenschr; 1996; 108(14):420-4. PubMed ID: 8784983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
    Guijarro C; Keane WF
    Miner Electrolyte Metab; 1996; 22(1-3):147-52. PubMed ID: 8676808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipidemia and progressive renal disease.
    Keane WF; Mulcahy WS; Kasiske BL; Kim Y; O'Donnell MP
    Kidney Int Suppl; 1991 Apr; 31():S41-8. PubMed ID: 2046270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The mevalonate pathway: importance in mesangial cell biology and glomerular disease.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    Miner Electrolyte Metab; 1993; 19(3):173-9. PubMed ID: 8232104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of lipid-lowering agents in the progression of renal disease.
    Keane WF; Kasiske BL; O'Donnell MP; Schmitz PG
    Am J Med; 1989 Nov; 87(5N):21N-24N. PubMed ID: 2486540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol synthesis inhibitors inhibit more than cholesterol synthesis.
    Kasiske BL; O'Donnell MP; Kim Y; Atluru D; Keane WF
    Kidney Int Suppl; 1994 Feb; 45():S51-3. PubMed ID: 8158898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid abnormalities in the nephrotic syndrome: the therapeutic role of statins.
    Wheeler DC
    J Nephrol; 2001; 14 Suppl 4():S70-5. PubMed ID: 11798150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular structures and lipids in progressive renal disease.
    Moorhead JF; Wheeler DC; Varghese Z
    Am J Med; 1989 Nov; 87(5N):12N-20N. PubMed ID: 2486539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression of renal failure: role of apolipoprotein B-containing lipoproteins.
    Attman PO; Samuelsson O; Alaupovic P
    Kidney Int Suppl; 1997 Dec; 63():S98-101. PubMed ID: 9407433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of increased glomerular protein traffic in the progression of renal failure.
    Bruzzi I; Benigni A; Remuzzi G
    Kidney Int Suppl; 1997 Nov; 62():S29-31. PubMed ID: 9350674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Is hyperlipidemia a factor in the progression of renal failure?].
    Geiger H
    Z Kardiol; 1993; 82 Suppl 4():35-8. PubMed ID: 8147060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lovastatin inhibits proliferation of rat mesangial cells.
    O'Donnell MP; Kasiske BL; Kim Y; Atluru D; Keane WF
    J Clin Invest; 1993 Jan; 91(1):83-7. PubMed ID: 8423236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mTOR inhibitor everolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat.
    Vogelbacher R; Wittmann S; Braun A; Daniel C; Hugo C
    Transplantation; 2007 Dec; 84(11):1492-9. PubMed ID: 18091526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes.
    Nosadini R; Tonolo G
    J Nephrol; 2003; 16 Suppl 7():S42-7. PubMed ID: 14733300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of statins on renal function.
    Agarwal R
    Am J Cardiol; 2006 Mar; 97(5):748-55. PubMed ID: 16490450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hyperlipidemia in human renal disease.
    D'Amico GD; Gentile MG
    Miner Electrolyte Metab; 1993; 19(3):196-204. PubMed ID: 8232107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low density lipoproteins and mitogenic signal transduction processes: role in the pathogenesis of renal disease.
    Kamanna VS
    Histol Histopathol; 2002 Apr; 17(2):497-505. PubMed ID: 11962755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipids and renal disease.
    Trevisan R; Dodesini AR; Lepore G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S145-7. PubMed ID: 16565240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.